TP53 and neoplasm: Its lack of association with response and survival to FOLFOX in this study (Tables 2 and 3) was therefore surprising and contrary to a large study reporting the impact of TP53 on patients with Dukes' C tumours treated with 5-fluorouracil as adjuvant chemotherapy (Russo et al, 2005).